Press Release
A Simple Tool Announces Launch of an A.I All-in-One Automated SEO Platform for Small Teams
-
An AI platform that unifies keyword research, content planning, generation, and publishing into a single automated workflow
Mumbai, MH, 29th January 2026, ZEX PR WIRE, A Simple Tool an all-in-one automated SEO platform, today announced its public launch, offering founders, marketers, and small teams a way to execute search engine optimization without relying on fragmented tools or large in-house SEO teams.
The platform is designed to automate the operational side of SEO, including competitor analysis, keyword discovery, content planning, article generation, and direct publishing to popular content management systems. The launch addresses a common challenge faced by growing digital businesses: maintaining consistent SEO execution with limited time and resources.
Search engine optimization continues to be a key acquisition channel globally. However, traditional SEO workflows often require multiple tools, manual coordination, and extended turnaround times, making them difficult to sustain for lean teams.
As a result, many companies either outsource SEO at high cost or deprioritize it altogether, despite its long-term impact on organic growth and customer acquisition.
A Simple Tool addresses this gap by consolidating the end-to-end SEO workflow into a single platform. The system analyzes a company’s website and competitors, generates a structured content plan, produces search-optimized articles, and publishes them automatically to platforms such as WordPress and Shopify.
By reducing manual intervention across research, writing, and publishing, the platform enables teams to run SEO as an ongoing process rather than a periodic or campaign-based initiative.
In addition to traditional search engines, the platform structures content to improve visibility in emerging answer-based discovery systems, including AI-powered assistants and large language models. This approach aligns content with how users increasingly discover information through both search queries and AI-generated answers.
Unlike conventional SEO software that focuses on isolated functions such as rank tracking or keyword suggestions, A Simple Tool emphasizes execution. The platform is designed to help non-specialist teams move from insight to published content with minimal operational overhead.
“SEO has become increasingly important, but also increasingly complex,” said Ruchit Kharwa, Owner of A Simple Tool. “Many small teams understand the value of organic traffic but struggle to execute consistently. This platform was built to simplify execution and make SEO more accessible as a day-to-day growth channel.”
Since its early availability, the platform has been adopted by startups, agencies, and small businesses across multiple regions, including North America, Europe, the Middle East, and Asia. Users have primarily adopted the tool to replace multi-tool SEO stacks and reduce dependence on external service providers.
Additional information about the platform and its capabilities is available at https://asimpletool.com.
About A Simple Tool
A Simple Tool is an all-in-one automated SEO platform that helps founders, marketers, and agencies plan, generate, and publish search-optimized content through a unified workflow. Owned and operated by Ruchit Kharwa, the company focuses on simplifying SEO execution through automation, consistency, and operational efficiency.
Tagline: All-in-One Automated SEO Tool
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.
Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.
The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.
This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health.
Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.
About Vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.
More About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- The U.S. FDA approval information can be found on the Incyte official website, as follows:
- The EMA approval information can be found on the Incyte official website, as follows:
- The clinical studies information can be found on the Opzelura® official website, as follows:
https://www.opzelura.com/opzelura-prescribing-information
- China Insights Consultancy’s industrial report
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation
Florida, US, 30th January 2026, ZEX PR WIRE, Most students don’t spend the start of summer walking across northern Spain. Gabriel Malkin did. In June 2025, the Florida high school graduate completed a 120-mile stretch of the Camino de Santiago, one of the world’s oldest pilgrimage routes. It wasn’t a last-minute idea. It was a goal he had planned for, trained for, and quietly worked toward for months.
This wasn’t about adventure or social media. For Gabriel, it was about setting a physical goal and showing up for it every day.
“I didn’t want to wing it,” he said. “It was important to take it seriously.”
Gabriel’s prep started long before his flight to Europe. He built up mileage slowly, starting with short daily walks in South Florida. As the months went on, he added distance, tested gear, and paid attention to recovery. Blisters, sore muscles, and weather were all part of the process. So was building patience.
“The Camino isn’t just hard because it’s long,” Gabriel said. “It’s hard because you have to get up and do it again every day. Even when you’re tired. Even when nothing hurts and you feel fine—you still have to walk.”
The daily rhythm became its own challenge. Mornings often started before sunrise, with quiet stretches of trail through farmland, hills, and towns. Gabriel carried a small pack with essentials. Water, snacks, extra socks. No Wi-Fi. No schedule beyond the day’s distance. Just a clear goal and a few hours of steady effort.
That focus and consistency mirrors how Gabriel approaches most things. Whether he’s in class, on the tennis court, or working on saxophone tone, he tends to favor structure and repetition over shortcuts. It’s not about perfection. It’s about showing up, improving slowly, and staying with it.
“I’ve never been the fastest or the strongest at anything,” he said. “But I like knowing I’m getting better, even if it’s slow.”
Gabriel grew up in South Florida and attended Virginia Shuman Young Elementary, Pine Crest in Fort Lauderdale, and NSU University School in Davie. He played tennis, baseball, and football through different stages of school. He also spent time hiking local trails and practicing saxophone, two interests he says helped him train for the Camino more than people might expect.
“Hiking helped with endurance, obviously,” he said. “But playing music teaches you a lot about repetition and listening to your body. You learn when to push and when to pause.”
For Gabriel, the Camino wasn’t a performance or a competition. It was a quiet personal test. He kept notes during the walk, not for a blog, but to track how each day felt. When he crossed the finish line in Santiago, there was no big moment. Just a quiet sense of completion.
Now back home, Gabriel hasn’t stopped walking. He’s back to local trails, early mornings, and training logs. He’s also thinking about what comes next—college, travel, more endurance goals—but isn’t rushing anything.
“There’s no rush,” he said. “The Camino reminded me that showing up every day matters more than trying to get somewhere fast.”
Gabriel Malkin Florida continues to build habits rooted in preparation, consistency, and follow-through. Whether through athletics, academics, or music, his focus remains steady: stay curious, stay active, and finish what you start.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Jon DiPietra, a New York–based real estate valuation executive, explains why common beliefs about space and value often miss the mark.
New York, US, 30th January 2026, ZEX PR WIRE, New York City is full of opinions about real estate. Many of them are repeated so often they start to feel true. But according to Jon DiPietra, decades of hands-on valuation work tell a different story.
“You learn things you cannot see in a report,” DiPietra says. “That’s where most of these myths fall apart.”
Below are five common myths that mislead everyday people across dense urban markets, why they persist, and what actually matters instead.
Myth 1: Bigger Space Always Means Better Value
Why people believe it:
Square footage is easy to compare. Listings highlight size first, so people assume more space equals more value.
The reality:
In dense cities, efficiency matters more than size. Studies show poorly used space can reduce productivity by up to 30 percent, even when square footage increases.
As DiPietra puts it, “The goal is not to produce the highest number. The goal is to produce something that makes sense in the real world.”
Try this today:
Identify one underused area in your home or office and repurpose it for a single clear function.
Myth 2: National Data Tells You Everything You Need to Know
Why people believe it:
Online tools and national reports feel authoritative and precise.
The reality:
Real estate is hyper-local. In New York, conditions can change block by block. National averages often lag reality by months.
“Real estate is ultimately driven by people, not formulas,” DiPietra says.
Try this today:
Walk your block at different times of day. Notice noise, foot traffic, and how spaces are actually used.
Myth 3: If a Space Worked Before, It Should Still Work Now
Why people believe it:
People resist change and assume layouts age well.
The reality:
How we live and work has shifted fast. Surveys show nearly 60 percent of people say their space no longer supports how they work today.
“Clear thinking matters more than being busy,” DiPietra notes.
Try this today:
Ask one simple question: What do I actually do here every day? Adjust one thing to support that reality.
Myth 4: More Information Leads to Better Decisions
Why people believe it:
Data feels safe. More feels smarter.
The reality:
Too much information can slow decisions and increase stress. Research links information overload to poorer judgment.
DiPietra says, “More data does not always lead to better decisions.”
Try this today:
Limit yourself to three criteria when evaluating a space or decision. Ignore the rest.
Myth 5: You Need a Major Renovation to Fix a Space
Why people believe it:
Media and social platforms spotlight dramatic transformations.
The reality:
Small changes often have outsized impact. Lighting, noise reduction, and decluttering consistently rank among the highest-return improvements.
“Sometimes the simplest changes create the most lasting value,” DiPietra says.
Try this today:
Improve lighting where you spend the most time. It is one of the fastest ways to change how a space feels.
If You Only Remember One Thing
Spaces influence behavior more than most people realize. When a space creates friction, it is often a design problem, not a personal one.
Understanding how space actually functions is more valuable than following assumptions or averages.
Call to Action
Share this myth list with someone who lives or works in a dense city. Pick one practical tip above and try it today. Small changes, applied intentionally, add up.
About Jon DiPietra
Jon DiPietra is a New York–based commercial real estate valuation executive and cofounder of H&T Appraisal, the valuation group of Horvath & Tremblay. With more than 20 years of experience, he has worked across residential, commercial, mixed-use, and special-use properties, focusing on how real people actually use space.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation
Jon DiPietra Debunks 5 Real Estate Myths That Mislead New Yorkers
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
Knybel Network Launches Focused Growth Campaign to Help Southeast Michigan Buyers and Homeowners Win in a Competitive Housing Market
-
Press Release1 week ago
Highly Recommended by GoodNight New York: Zeagoo Patterned Shirt Becomes the Focal Point of Early Spring Outfits
-
Press Release6 days ago
New Findings Reveal a Hidden Indoor Air Quality Crisis Linked to Aging HVAC Systems and Fiberglass Ductwork Across South Florida
-
Press Release6 days ago
Stockity Arrives in Indonesia, Bringing Global Markets Closer to Local Traders
-
Press Release6 days ago
Karviva Selected to Meet with Costco Wholesale Southern California Merchants at Upcoming Local Summit
-
Press Release6 days ago
GOD55 Sports Announced as Gold Partner and Official Sports Media Partner for WPC Malaysia Series 2025-26
-
Press Release7 days ago
Rankiteo Opens Global Tender for Cyber Insurers: Exclusive Access to 5 million Enterprise Profiles and the Future of Cyber Insurance Distribution
-
Press Release7 days ago
Inside Bengaluru’s New Urban Escape: How Casasaga Is Redefining City Staycations